Dean Aguiar, PhD daguiar@tscalliance.org 

Vice President, Translational Research

 

Zoë Fuchs • zfuchs@tscalliance.org

Senior Manager, Translational Research 

 

TSC Alliance Preclinical Consortium  

American Epilepsy Society • Poster in Collaboration with PsychoGenics, Inc.

Poster Session 1 • Saturday, December 6, 2025, 12:00-5:00 pm

Poster #1.203 • “mTOR Inhibitors Decrease Seizures and Enhance Survival in a Mouse Model of Tuberous Sclerosis Complex (TSC)”

Please stop by our booth #639 to connect with our team and learn more about us!

PSTR320.20 | 8857 

 

Title: Dose-response of mTOR inhibitors in a nonclinical model of tuberous sclerosis complex (TSC) associated epilepsy – Conducted by the TSC Preclinical Consortium (See pg. 149) 

TSC Animal Models (epilepsy and/or behavioral) 

  • Tsc1 & Tsc2 stochastic models   

Selected Publications:  

The role of the TSC Alliance in advancing therapy development: a patient organization perspective 

Inhibition of MEK-ERK Signaling Reduces Seizures in Two Mouse Models of Tuberous Sclerosis Complex 

Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death 

Chemical Biology Screening Identifies a Vulnerability to Checkpoint Kinase Inhibitors in TSC2-Deficient Renal Angiomyolipoma